Personalized Dosing Algorithm for Complement Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current personalized dosing strategies for complement inhibitors are inefficient, leading to suboptimal treatment outcomes, financial waste, and increased risk of adverse effects in patients, particularly in conditions like thrombotic microangiopathy (TMA) following hematopoietic stem cell transplantation (HSCT), due to lack of precise monitoring and variable drug clearance.
Innovation Solution
A method and system for determining personalized dosing schedules of complement inhibitors like eculizumab based on pre-treatment plasma sC5b-9 concentrations and body weight, using pharmacokinetic and pharmacodynamic markers to maintain therapeutic levels and prevent toxicity, involving real-time monitoring and adjustment of dosing intervals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standardized dosing schedules are used for complement inhibitors, then ease of administration is improved, but treatment effectiveness deteriorates due to variable drug clearance and lack of personalized dosing
Solution Approach 1:
The patent performs preliminary pharmacokinetic testing before treatment to determine individualized dosing parameters. By measuring drug clearance rates and volume of distribution in advance, the system establishes personalized dosing schedules that maintain therapeutic effectiveness while simplifying ongoing administration.
Solution Approach 2:
The patent changes dosing parameters (dose amount, frequency, duration) based on individually determined pharmacokinetic parameters such as clearance rate and volume of distribution. This allows customization of dosing schedules to match each patient's metabolic characteristics, ensuring effective treatment while maintaining ease of administration.
2Reliability
If higher doses of complement inhibitor are administered, then treatment effectiveness is improved, but financial cost and risk of adverse effects increase
Solution Approach 1:
The patent adjusts dosing parameters based on individually determined pharmacokinetic characteristics. By calculating optimal doses using measured clearance rates and volume of distribution, the system achieves effective treatment at the minimum necessary dose, avoiding both under-dosing and excessive dosing that could cause adverse effects.
Solution Approach 2:
The patent uses pharmacokinetic testing results as feedback to optimize dosing regimens. By measuring drug concentration, clearance rate, and volume of distribution, the system continuously adjusts dosing parameters to maintain therapeutic levels while minimizing toxicity and adverse effects.
3Measurement precision
If pharmacokinetic testing is performed to determine personalized dosing, then treatment precision is improved, but device complexity and testing requirements increase
Solution Approach 1:
The patent performs comprehensive pharmacokinetic testing before treatment begins, establishing all necessary dosing parameters in advance. This preliminary action captures the complexity upfront, allowing for simplified personalized dosing schedules during actual treatment administration.
Solution Approach 2:
The patent replaces complex ongoing monitoring and adjustment mechanisms with upfront pharmacokinetic testing. By determining clearance rates and volume of distribution through initial testing, the system eliminates the need for continuous complex monitoring during treatment, substituting mechanical/operational complexity with initial analytical measurement.
Data Source
AI summary
Described are methods and systems for the treatment of individuals having a disorder characterized by complement system dysregulation. The described methods and systems may be used for a variety of purposes, including for example, establishing one or both of a general or personalized dosing schedule for treatment using a complement inhibitor, establishing a dosage schedule sufficient to maintain an effective amount of complement inhibitor, establishing general dosing schedules for novel complement modifying agents and identifying a treatment regimen and/or dose eliminating the possibility of under dosing medication, and treatment regimen and/or dose for reducing or preventing toxicity in a patient.